Guilingji capsule for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial.

التفاصيل البيبلوغرافية
العنوان:	Guilingji capsule for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial.
المؤلفون:	Ming Z; Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China., Yimiao L; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China., Huichan W; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China., Yu C; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China., Lina MA; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China., Hui P; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China., Hao LI; Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China.
المصدر:	Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan [J Tradit Chin Med] 2023 Oct; Vol. 43 (5), pp. 1019-1025.
نوع المنشور:	Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: Academy Of Traditional Chinese Medicine Country of Publication: China NLM ID: 8211546 Publication Model: Print Cited Medium: Internet ISSN: 2589-451X (Electronic) Linking ISSN: 02552922 NLM ISO Abbreviation: J Tradit Chin Med Subsets: MEDLINE
أسماء مطبوعة:	Publication: Beijing : Academy Of Traditional Chinese Medicine Original Publication: [Beijing, China : Pub. Office, Journal of Traditional Chinese Medicine, 1981-
مواضيع طبية MeSH:	Acetylcholinesterase* , Alzheimer Disease*/drug therapy, Humans ; Activities of Daily Living ; Quality of Life ; bcl-2-Associated X Protein ; Plant Extracts
مستخلص:	Objective: To investigate the effectiveness and safety of Guilingji capsule (, GLJC) in treatment of Alzheimer's disease (AD) patients with kidney-marrow deficiency pattern (KMDP) compared with gingko extract tablets. Methods: This is a secondary analysis of a large-scale multicenter randomized non-inferiority clinical trial. A total of 120 AD patients with KMDP were enrolled in this study. The participants were randomly categorized into two groups: (a) GLJC group ( = 60) and (b) gingko group ( = 60). The GLJC group was treated with GLJC and gingko extract mimetic tablets, whereas the gingko group received gingko extract tablets and mimetic GLJC. The data on the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Activities of Daily Living (ADL), and Chinese Medicine Symptom Scale (CM-SS) was evaluated at 0, 12, and 24 weeks of treatment. The serum levels of acetylcholine (Ach), acetylcholinesterase (AchE), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax) in the participants were measured before and after 24 weeks of treatment. The safety was based on the incidence of adverse events. Results: Both interventions significantly increased the MMSE scores of the participants and decreased their ADAS-Cog, ADL, and CM-SS scores ( < 0.01). Compared with the gingko group, the GLJC group had a higher effective rate of improvement in the symptoms of "amnesia" and "dull expression and slow thinking" at the 12th week and 24th week ( < 0.05, < 0.01). In the GLJC group, serum Bcl-2 levels were significantly increased at the 24th week ( < 0.05). Serum Bax and AchE levels of the two groups were significantly decreased at the 24th week ( < 0.01). No treatment-related adverse events were reported in the two groups. Conclusions: GLJC is equivalent to the gingko extract tablets in terms of improving cognitive function and the quality of life in AD patients with KMDP and has good clinical efficacy and safety. When it comes to improving TCM symptoms and anti-aging, GLJC is even more advantageous.
References:	Eur J Pharmacol. 2020 Nov 15;887:173554. (PMID: 32941929) Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606) J Ethnopharmacol. 2020 Jun 12;255:112734. (PMID: 32151756) Neurobiol Learn Mem. 2021 Sep;183:107484. (PMID: 34175450) Front Neurosci. 2018 Feb 06;12:37. (PMID: 29467605) Biochem Pharmacol. 2014 Apr 15;88(4):640-51. (PMID: 24398425) Alzheimers Dement. 2018 Feb;14(2):205-214. (PMID: 28943286) Alzheimers Dement. 2022 Apr;18(4):700-789. (PMID: 35289055) J Pharm Anal. 2022 Jun;12(3):460-469. (PMID: 35811626) Alzheimers Dement. 2021 Jun;17(6):1066-1071. (PMID: 33682261) Rejuvenation Res. 2020 Apr;23(2):138-149. (PMID: 30982406) Int J Mol Sci. 2017 Jan 28;18(2):. (PMID: 28134846) Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. (PMID: 25858345) Mayo Clin Proc. 1996 Sep;71(9):829-37. (PMID: 8790257) Lancet Public Health. 2020 Dec;5(12):e661-e671. (PMID: 33271079) Front Public Health. 2020 Oct 21;8:557587. (PMID: 33194959) Br J Nutr. 2015 Jul 14;114(1):1-14. (PMID: 25997382) J Ethnopharmacol. 2019 Jun 28;238:111839. (PMID: 30928501) Molecules. 2020 Dec 08;25(24):. (PMID: 33302541) Biomolecules. 2020 Dec 04;10(12):. (PMID: 33291826) Nature. 2021 Feb;590(7844):122-128. (PMID: 33473210) Chin J Integr Med. 2020 Aug;26(8):577-582. (PMID: 32761337) Immunotherapy. 2019 Jan;11(1):3-6. (PMID: 30702009) Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250) N Engl J Med. 2012 Mar 8;366(10):893-903. (PMID: 22397651) Ann Intern Med. 2010 Jun 1;152(11):726-32. (PMID: 20335313)
فهرسة مساهمة:	Keywords: Alzheimer disease; Guilingji capsule; gingko extract tablets; kidney-marrow deficiency pattern; randomized controlled trial
المشرفين على المادة:	0 (guilingji) EC 3.1.1.7 (Acetylcholinesterase) 0 (bcl-2-Associated X Protein) 0 (Plant Extracts)
تواريخ الأحداث:	Date Created: 20230908 Date Completed: 20230911 Latest Revision: 20231016
رمز التحديث:	20240628
مُعرف محوري في PubMed:	PMC10465832
DOI:	10.19852/j.cnki.jtcm.20230404.006
PMID:	37679990
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	2589-451X
DOI:	10.19852/j.cnki.jtcm.20230404.006